CytRx Corporation To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 American Association for Cancer Research Annual Meeting

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that positive preclinical results from an in vivo study of aldoxorubicin in an animal model of glioblastoma will be presented at the American Association for Cancer Research Annual Meeting being held April 5-9, 2014 in San Diego, CA.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC